tbuckley/cabot-search huggingface dataset:
Observational study of real world clinical performance of microrna molecular profiling for cancer of unknown primary (CUP).
Authors: Mats Olot Sanden, Robert Wassman, Karin Ashkenazi, Hila Benjamin, Yael Spector, Eran Goren
Journal: Journal of Clinical Oncology (2013)

e22173 Background: Molecular profiling of CUP may effectively identify the underlying tumor type and potentially influence treatment decisions and outcomes. A microRNA (miR) array has been shown in concordance studies at leading academic centers to perform well in correctly identifying the tumor of origin in CUP. This series of consecutive referrals tested in a CLIA-laboratory extends these findings to the real world clinical setting. Methods: MicroRNA was isolated from 258 consecutive specimens referred to Rosetta Genomics, analyzed on a 64 miR-based array, and interpreted for any of 42 specific tumor types as previously described. The laboratory medical director routinely collected follow-up information on correlation of test prediction with other clinical information, pathology findings, supplemental IHC, treatment response, and clinical course as well as physician perception of relevance and utility of test result. This information was scored categorically into 3 classes of concordance depending on agreement with clinical and/or pathological data. The composite data was de-identified and analyzed for assessment of overall test performance in this real world clinical setting. Results: Of 258 specimens submitted 90% were paraffin embedded tissue (FFPE). Sufficient tumor material was received in 217 (85%) cases, of which 192 (88%) were successfully processed and reported with a mean TAT of 7 days. The most common result was colorectal (12%), followed by breast (10.4%), upper body squamous cell (7.3%), ovarian (6.8%), and biliary tract/pancreatic (6.8%); and the remaining 109 cases (57%) represented 30 additional tumor types. Overall the concordance with the clinical and/or pathological best final diagnosis was 86%, and when the reporting algorithm yielded a single diagnosis (51% of cases) the concordance was 89%. Clinical utility as measured by consideration of a shift in therapy or significantly increased decisional certainty for therapy was observed in approximately 70% of the cases. Conclusions: MicroRNA analysis in CUP cases performs comparably in the real world setting to that previously reported in academic studies and adds information of value to the management of patients.
(De)form and Function: Measuring Cellular Forces with Deformable Materials and Deformable Structures
Authors: Ava M. Obenaus, Molly Y. Mollica, Nathan J. Sniadecki
Journal: Advanced Healthcare Materials (2020)

Abstract The ability for biological cells to produce mechanical forces is important for the development, function, and homeostasis of tissue. The measurement of cellular forces is not a straightforward task because individual cells are microscopic in size and the forces they produce are at the nanonewton scale. Consequently, studies in cell mechanics rely on advanced biomaterials or flexible structures that permit one to infer these forces by the deformation they impart on the material or structure. Herein, the scientific progression on the use of deformable materials and deformable structures to measure cellular forces are reviewed. The findings and insights made possible with these approaches in the field of cell mechanics are summarized.
Sorafenib in Advanced Non-Small-Cell Lung Cancer: A Retrospective Analysis of Patients in Progression After Two or More Lines of Therapy
Authors: S. Vazquez-Estevez, S. Varela, B. Campos, R. Garcia-Campelo, E. Alvarez, G. Quintero, L. Anton-Aparicio, J.R. Mel
Journal: Annals of Oncology (2012)
Phase IB Study of Vemurafenib in Combination with the Mek Inhibitor, GDC-0973, in Patients (PTS) with Unresectable or Metastatic BRAFV600 Mutated Melanoma (BRIM7)
Authors: R. Gonzalez, A. Ribas, A. Daud, A. Pavlick, T.F. Gajewski, I. Puzanov, M.S.L. Teng, I. Chan, N.W. Choong, G. McArthur
Journal: Annals of Oncology (2012)
High-Resolution Late Gadolinium Enhancement Magnetic Resonance for the Diagnosis of Myocardial Infarction With Nonobstructed Coronary Arteries
Authors: Pierre-Francois Lintingre, Hubert Nivet, Stéphanie Clément-Guinaudeau, Claudia Camaioni, Soumaya Sridi, Olivier Corneloup, Edouard Gerbaud, Pierre Coste, Gael Dournes, Valérie Latrabe, Francois Laurent, Michel Montaudon, Hubert Cochet
Journal: JACC. Cardiovascular imaging (2020)

The aim of this study was to assess the diagnostic yield of cardiac magnetic resonance (CMR) including high-resolution (HR) late gadolinium enhancement (LGE) imaging using a 3-dimensional respiratory-navigated method in patients with myocardial infarction with nonobstructed coronary arteries (MINOCA).CMR plays a pivotal role for the diagnosis of patients with MINOCA. However, the diagnosis remains inconclusive in a significant number of patients, the results of CMR being either negative or uncertain (i.e., compatible with multiple diagnoses).Consecutive patients categorized as having MINOCA after blood testing, electrocardiography, coronary angiography, and echocardiography underwent conventional CMR, including cine, T2-weighted, first-pass perfusion, and conventional breath-held LGE imaging. HR LGE imaging using a free-breathing method allowing improved spatial resolution (voxel size 1.25 × 1.25 × 2.5 mm) was added to the protocol when the results of conventional CMR were inconclusive and was optional otherwise. Diagnoses retained after reviewing conventional CMR were compared with those retained after the addition of HR LGE imaging.From 2013 to 2016, 229 patients were included (mean age 56 ± 17 years, 45% women). HR LGE imaging was performed in 172 patients (75%). In this subpopulation, definite diagnoses were retained after conventional CMR in 86 patients (50%): infarction in 39 (23%), myocarditis in 32 (19%), takotsubo cardiomyopathy in 13 (8%), and other diagnoses in 2 (1%). In the remaining 86 patients (50%), results of CMR were inconclusive: negative in 54 (31%) and consistent with multiple diagnoses in 32 (19%). HR LGE imaging led to changes in final diagnosis in 45 patients (26%) and to a lower rate of inconclusive final diagnosis (29%) (p < 0.001). In particular, HR LGE imaging could reveal or ascertain the diagnosis of infarction in 14% and rule out the diagnosis of infarction in 12%. HR LGE imaging was particularly useful when the results of transthoracic echocardiography, ventriculography, and conventional CMR were negative, with a 48% rate of modified diagnosis in this subpopulation.HR LGE imaging has high diagnostic value in patients with MINOCA and inconclusive findings on conventional CMR. This has major diagnostic, prognostic, and therapeutic implications.
Gut commensal derived-valeric acid protects against radiation injuries
Authors: Yuan Li, Jiali Dong, Huiwen Xiao, Shuqin Zhang, Bin Wang, Ming Cui, Saijun Fan
Journal: Gut Microbes (2020)

Hematopoietic and intestinal systems side effects are frequently found in patients who suffered from accidental or medical radiation exposure. In this case, we investigated the effects of gut microbiota produced-valeric acid (VA) on radiation-induced injuries.Mice were exposed to total body irradiation (TBI) or total abdominal irradiation (TAI) to mimic accidental or clinical scenarios. High-performance liquid chromatography (HPLC) was performed to assess short-chain fatty acids (SCFAs) in fecal pellets. Oral gavage with VA was used to mitigate radiation-induced toxicity. Gross examination was performed to assess tissue injuries of thymus, spleen and small intestine. High-throughput sequencing was used to characterize the gut microbiota profile. Isobaric tags for relative and absolute quantitation (iTRAQ) were performed to analyze the difference of protein profile. Hydrodynamic-based gene delivery assay was performed to silence KRT1 in vivo.VA exerted the most significant radioprotection among the SCFAs. In detail, VA replenishment elevated the survival rate of irradiated mice, protected hematogenic organs, improved gastrointestinal (GI) tract function and intestinal epithelial integrity in irradiated mice. High-throughput sequencing and iTRAQ showed that oral gavage of VA restored the enteric bacteria taxonomic proportions, reprogrammed the small intestinal protein profile of mice following TAI exposure. Importantly, keratin 1 (KRT1) played a pivotal role in the radioprotection of VA.Our findings provide new insights into gut microbiota-produced VA and underpin that VA might be employed as a therapeutic option to mitigate radiation injury in pre-clinical settings.
BEPO®: Bioresorbable diblock mPEG-PDLLA and triblock PDLLA-PEG-PDLLA based in situ forming depots with flexible drug delivery kinetics modulation
Authors: Christophe Roberge, Jean-Manuel Cros, Juliette Serindoux, Marie-Emérentienne Cagnon, Rémi Samuel, Tjasa Vrlinic, Pierre Berto, Anthony Rech, Joël Richard, Adolfo Lopez-Noriega
Journal: Journal of Controlled Release (2020)

This article presents BEPO®, an in situ forming depot (ISFD) technology mediated by a solvent-exchange mechanism. The matrix of the in situ formed drug delivery depot is composed of the combination of a diblock (DB) and a triblock (TB) polyethylene glycol-polyester copolymer. This combination offers a broad capability to tune the release of a wide variety of drugs to the desired pharmacokinetics. The work described in the present article demonstrates that the delivery rate and profile can be adjusted by changing the composition of either TB or DB or the relative ratio between them, among other parameters. It has been shown that the polymeric composition of the formulation has a substantial impact on the solvent exchange rate between the organic solvent and the surrounding aqueous medium which subsequently determines the internal structure of the resulting depot and the delivery of the therapeutic cargo. This has been demonstrated studying the in vitro release of two model molecules: bupivacaine and ivermectin. Formulations releasing these drugs have been administered to animal models to show the possibility of delivering therapeutics from weeks to months by using BEPO® technology.
Osteogenic Hydrogels: Gelatin Templated Polypeptide Co‐Cross‐Linked Hydrogel for Bone Regeneration (Adv. Healthcare Mater. 1/2020)
Authors: Yusen Qiao, Xingzhi Liu, Xichao Zhou, Hongbo Zhang, Wen Zhang, Wei Xiao, Guoqing Pan, Wenguo Cui, Hélder A. Santos, Qin Shi
Journal: Advanced Healthcare Materials (2020)

In article number 1901239 by Wenguo Cui, Hélder A. Santos, Qin Shi, and co-workers, a photo-crosslinked osteogenic growth peptide is constructed by solid-state synthesis, and then co-crosslinked with photo-crosslinked gelatin by UV-radiation to create a novel osteogenic polypeptide hydrogel to promote long term bone regeneration. The co-crosslinked polypeptide can strengthen the mechanical property of the defect bone and avoid burst osteogenic peptides, releasing during the bone defect healing period.
P4.01 Delivery of High Quality Molecular Panel Tests for 9,000 Cancer Patients Routinely Consented for Use of Molecular and Clinical Data
Authors: H.F. Peach, P.W.M. Johnson, S. Johnson, L.K. Jones, M. Jones, R. Sharpe, E. Shaw, T. Turtiainen, A. Tuff
Journal: Annals of Oncology (2012)
Attention Study: Asian Trial of Tivantinib Plus Erlotinib Versus Erlotinib for NSCLC without EGFR Mutation; a Phase 3 Trial with a Personalized Dose Setting Based on Pretreatment Test for CYP2C19 Polymorphism
Authors: K. Park, C.-M. Tsai, N. Yamamoto, T. Mitsudomi, K. Nakagawa
Journal: Annals of Oncology (2012)
Somatostatin Receptor (SSTR) Expression and Proliferative Index (KI 67) in 100 Patients (PTS) with Gastroenteropancreatic Neuroendocrine Tumors (Gep-Nets). Clinical-Pathological Correlation
Authors: J.M. Oconnor, S. Belli, V. Pesce, C. Bestani, G. Mendez, E. Dominichini, A. Cabanne, G. Lopez, F. Marmissolle, E. Roca
Journal: Annals of Oncology (2012)
Retrospective Study of Clinicopathologic Factors Associated with Alk Rearrangement and Survival Outcome in Chinese Patients (PTS) with NSCLC
Authors: X. Zhang, C. Blanckmeister, Y. Cheng, D. Wu, J. Yang, H. Tian, J. Chen, Z. Xie, H. Yan, Y. Wu
Journal: Annals of Oncology (2012)
Abstract 15146: Enhancing Mobile Health to Achieve Both Hypertension and Diabetes Goals
Authors: Mansur Shomali, Vinayak Shenoy, Richard J Katz, Malinda Peeples
Journal: Circulation (2019)

Introduction: Optimizing the treatment of hypertension, a common comorbidity with type 2 diabetes (DM2), is frequently not achieved. Starting in late 2018, blood pressure tracking was added as a fe...
A Randomized Phase III Study of a Cisplatin (CDDP) and Docetaxel (DOC) with or without Irinotecan (CPT) in Patients with Advanced NSCLC: Okayama Lung Cancer Study Group OLCSG 0403 Trial
Authors: E. Ichihara, A. Hisamoto, S. Harita, Y. Segawa, H. Kamei, T. Shibayama, K. Gemba, K. Hotta, K. Matsuo, K. Aoe, N. Takigawa, M. Tabata, K. Matsuo, M. Tanimoto, K. Kiura
Journal: Annals of Oncology (2012)
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Authors: Douglas B. Johnson, Fengmin Zhao, Marcus Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Shuli Li, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanly R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Substantial preclinical evidence and case reports suggest that MEK inhibition is an active approach in tumors with BRAF mutations outside the V600 locus, and in BRAF fusions. Thus, Subprotocol R of the NCI-MATCH study tested the MEK inhibitor trametinib in this population. Patients and Methods: The NCI-MATCH study performed genomic profiling on tumor samples from patients with solid tumors and lymphomas progressing on standard therapies or with no standard treatments. Patients with prespecified fusions and non-V600 mutations in BRAF were assigned to Subprotocol R using the NCI-MATCHBOX algorithm. The primary endpoint was objective response rate (ORR). Results: Among 50 patients assigned, 32 were eligible and received therapy with trametinib. Of these, 1 had a BRAF fusion and 31 had BRAF mutations (13 and 19 with class 2 and 3 mutations, respectively). There were no complete responses; 1 patient (3%) had a confirmed partial response (patient with breast ductal adenocarcinoma with BRAF G469E mutation) and 10 patients had stable disease as best response (clinical benefit rate 34%). Median progression-free survival (PFS) was 1.8 months, and median overall survival was 5.7 months. Exploratory subgroup analyses showed that patients with colorectal adenocarcinoma (n = 8) had particularly poor PFS. No new toxicity signals were identified. Conclusions: Trametinib did not show promising clinical activity in patients with tumors harboring non-V600 BRAF mutations, and the subprotocol did not meet its primary endpoint.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Authors: Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti, Guillermo Garcia-Manero, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Mario Cazzola, Osman Ilhan, Mikkael A. Sekeres, José F. Falantes, Beatriz Arrizabalaga, Flavia Salvi, Valentina Giai, Paresh Vyas, David Bowen, Dominik Selleslag, Amy E. DeZern, Joseph G. Jurcic, Ulrich Germing, Katharina S. Götze, Bruno Quesnel, Odile Beyne-Rauzy, Thomas Cluzeau, Maria-Teresa Voso, Dominiek Mazure, Edo Vellenga, Peter L. Greenberg, Eva Hellström-Lindberg, Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Aziz Benzohra, Jennie Zhang, Anita Rampersad, Diana R. Dunshee, Peter G. Linde, Matthew L. Sherman, Rami S. Komrokji, Alan F. List
Journal: New England Journal of Medicine (2020)

Patients with anemia and lower-risk myelodysplastic syndromes in whom erythropoiesis-stimulating agent therapy is not effective generally become dependent on red-cell transfusions. Luspatercept, a recombinant fusion protein that binds transforming growth factor β superfamily ligands to reduce SMAD2 and SMAD3 signaling, showed promising results in a phase 2 study.In a double-blind, placebo-controlled, phase 3 trial, we randomly assigned patients with very-low-risk, low-risk, or intermediate-risk myelodysplastic syndromes (defined according to the Revised International Prognostic Scoring System) with ring sideroblasts who had been receiving regular red-cell transfusions to receive either luspatercept (at a dose of 1.0 up to 1.75 mg per kilogram of body weight) or placebo, administered subcutaneously every 3 weeks. The primary end point was transfusion independence for 8 weeks or longer during weeks 1 through 24, and the key secondary end point was transfusion independence for 12 weeks or longer, assessed during both weeks 1 through 24 and weeks 1 through 48.Of the 229 patients enrolled, 153 were randomly assigned to receive luspatercept and 76 to receive placebo; the baseline characteristics of the patients were balanced. Transfusion independence for 8 weeks or longer was observed in 38% of the patients in the luspatercept group, as compared with 13% of those in the placebo group (P<0.001). A higher percentage of patients in the luspatercept group than in the placebo group met the key secondary end point (28% vs. 8% for weeks 1 through 24, and 33% vs. 12% for weeks 1 through 48; P<0.001 for both comparisons). The most common luspatercept-associated adverse events (of any grade) included fatigue, diarrhea, asthenia, nausea, and dizziness. The incidence of adverse events decreased over time.Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event. (Funded by Celgene and Acceleron Pharma; MEDALIST ClinicalTrials.gov number, NCT02631070; EudraCT number, 2015-003454-41.).
Small RNAs in the Transgenerational Inheritance of Epigenetic Information
Authors: Lea Duempelmann, Merle Skribbe, Marc Bühler
Journal: Trends in Genetics (2020)

In recent years it has become evident that RNA interference-related mechanisms can mediate the deposition and transgenerational inheritance of specific chromatin modifications in a truly epigenetic fashion. Rapid progress has been made in identifying the RNAi effector proteins and how they work together to confer long-lasting epigenetic responses, and initial studies hint at potential physiological relevance of such regulation. In this review, we highlight mechanistic studies in model organisms that advance our understanding of how small RNAs trigger long-lasting epigenetic changes in gene expression and we discuss observations that lend support for the idea that small RNAs might participate in mechanisms that trigger epigenetic gene expression changes in response to environmental cues and the effects these could have on population adaptation.
Standard Thoracic Radiotherapy with or without Concurrent Daily Low-Dose Carboplatin in Elderly Patients with Locally Advanced Non-Small Cell Lung Cancer: A Phase III Trial of the Japan Clinical Oncology Group (JCOG0301)
Authors: T. Shukuya, N. Yamamoto, S. Atagi, M. Kawahara, A. Yokoyama, H. Okamoto, Y. Ohe, T. Sawa, T. Shinkai, K. Mori, K. Takeda, S. Ishikura, T. Shibata, N. Saijo, T. Tamura
Journal: Annals of Oncology (2012)
Treatment of Patients with Hormone Receptor (HR)-Positive and HER2-Positive Locally Advanced or Metastatic BC with a Combination of Pertuzumab and Trastuzumab Plus an Aromatase Inhibitor (AI): an Open-Label Randomised Phase II Study (Pertain)
Authors: G. Arpino, C. Poole, J. Ferrero, J.R. La De Haba, L. Mitchell, C. Pelizon, M.F. Rimawi
Journal: Annals of Oncology (2012)
Studying New Approaches to Detect Atrial Fibrillation
Authors: Jennifer Abbasi
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Maintenance therapy with arsenic after induction in an alternative and long-term case for the prevention of recurrence of acute promyelocytic leukemia during the period between November 2005 and December 2011.
Authors: Mozaffar Aznab, Ghobad Salimi, Jafar Navabi, Touraj Jouybari, Mansour Rezaei, Mari Ataee, Kaveh Kavianimoghadam, Farhoud Totoonchian, Kamran Alimoghaddam
Journal: Journal of Clinical Oncology (2012)

6556 Background: Arsenic trioxide has been used in the first line treatment of acute promyelocytic leukemia and also for recurrence after ATRA and chemotherapy. In this study, it we used it in induction of remission and maintenance therapy Methods: Between November 2005 to December 2011, 42 patients admitted in our department with APL diagnosis. There were 27 male and 15 women with a median age of 28 years. Arsenic trioxide started at 0.15 mg/kg intravenous infusion till patient’s bone marrows achieve to complete remission. Then, after 28 days rest, we did consolidation with Arsenic trioxide with the same dosage for 28 more days. We continued treatment with 14 days courses of Arsenic trioxide every 3-4 months for 2 years, as maintenance therapy Results: Four patients died during the first 20 days of treatment. Thirty-eight patients achieved to remission. Two patients refused to continue treatment after achieving to remission and excluded from this study. Thirty-six patients finished whole treatment. After a median follow-up of 54 months, 4 patients died due to disease relapse and one patient relapsed and initiated treatment with Arsenic and ATRA. Five patients faced leukocytosis over 100,000/ml. In these cases we were obligated to discontinue Arsenic for 3-4 days and did chemotherapy by Danourobicin for 2 days. Totally 8 patients died during remission induction and long-term follow up. One year, 3 and 5 years RFS were 97%, 87.1% and 79.4 respectively and we didn’t observe any relapse for patients who remained in remission after 5 years. Finally, 31 patients are alive and free of disease. The overall survival was 79.5% for our cohort. Conclusions: Arsenic trioxide is an effective treatment as the first line therapy for new cases of APL and long term therapy with will reduce the risk of diseases recurrence without any major toxicity in long time.
Phase I Study to Compare Safety and Pharmacokinetics of Afatinib, An Oral Irreversible Erbb Family Blocker, in Non-Cancer Subjects with Hepatic Impairment to Matched Healthy Subjects
Authors: D. Schnell, S. Buschke, H. Fuchs, R. Göldner, M. Uttenreuther-Fischer, P. Stopfer, S. Wind, A. Halabi, R. Koenen
Journal: Annals of Oncology (2012)